Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 01, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of July 31, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital: 6,021,463,342 Ordinary shares of 25p each.
- Treasury Shares: 329,499,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,691,964,184.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period regarding financial performance or capital structure.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share counts intended for shareholder calculation purposes under Financial Services Authority rules.
Important Facts for Investors
- Investors should verify the total number of voting rights (5,691,964,184) as the denominator for determining notification requirements under Disclosure and Transparency Rules.
- The Company holds a significant portion of its issued shares (329,499,158) in Treasury, which are excluded from the voting rights count.
- This filing does not contain financial performance data; investors must refer to other reports for revenue and earnings information.